John Delaney is most famous at this point for getting dunked on by Elizabeth Warren in a near-campaign-ending jab on health care. So, can this guy actually do anything positive for America’s HIV epidemic?
All over the U.S., people taking PrEP are being urged to go with Descovy instead of Truvada. Our HIV prevention expert answers the question: Is it worthwhile to make the switch?
Carl Siciliano and Alex Roque talk about the first leadership turnover at New York City’s Ali Forney Center since its 2002 founding.
For Black New Yorkers, HIV Progress Is Challenged by Housing Costs and Trump Anti-Immigrant Policies
Despite the Big Apple’s HIV rates falling for everyone, Black New Yorkers still are the most vulnerable.
HIV prevention specialist Damon L. Jacobs argues that by building on her strengths, Sen. Klobuchar could make headway in fighting the United States HIV epidemic.
St. Louis–based advocate and educator Joan Ferguson talks about HIV work then and now.
“PrEP is our number-one priority, but it’s not easy. There’s a lot of misconceptions and misinformation out there.”
In this article reprinted from The Conversation, two researchers discuss the importance of their recent study findings.
One of the persisting fears people may have when starting PrEP is wondering whether a risk remains of contracting HIV while on PrEP without using an additional barrier method.
We're telling the stories of the people and places that will be profoundly affected by the "Ending the HIV Epidemic" plan as it unfolds, and seeking to answer the question: Can this plan truly end HIV transmission in the U.S.?